Experimental transplantation: Novel immunosuppression using the JAK3-inhibitor R348

Keyphrases

• Active Metabolite 20%
• Acute Cardiac Rejection 20%
• Acute Cellular Rejection 20%
• Acute Rejection 60%
• Airway Morphology 20%
• Allograft Survival 20%
• Antibody Production 20%
• Biological Activity 20%
• Cardiac Allograft 20%
• Combination Regimen 20%
• Disease Development 40%
• Donor-specific Antibodies 20%
• Drug Toxicity 20%
• Efficacy-toxicity 20%
• Enzyme Inhibition 20%
• Experimental Transplantation 100%
• Gene Expression 20%
• Graft Function 20%
• Heterotopic 20%
• Histologic 20%
• IL-6 Expression 20%
• Immune Cells 20%
• In Vitro Enzyme Assay 20%
• In Vitro Inhibition 20%
• Infiltration 20%
• Interferon-γ 20%
• JAK3 40%
• JAK3 Inhibitor 100%
• Janus Kinase 20%
• Novel Immunosuppression 100%
• Obliterative Airway Disease 80%
• Pharmacokinetics 40%
• Physiologic 20%
• Plasma Parameters 20%
• Rapamycin 100%
• Selective Inhibition 20%
• Signal Transduction 20%
• Subtherapeutic 20%
• Synergistic Interaction 20%
• Tacrolimus 80%
• Th1-Th2 20%
• Tracheal Transplantation 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Active Metabolite 20%
• Acute Graft Rejection 60%
• Antibodies 20%
• Biological Activity 20%
• Cardiac Graft Rejection 20%
• Chronic Graft Rejection 20%
• Disease Course 40%
• Drug Toxicity 20%
• Enzyme Inhibition 20%
• Immunosuppressive Agent 20%
• Janus Kinase 20%
• Janus Kinase 3 Inhibitor 100%
• Pharmacokinetics 20%
• Rapamycin 100%
• Respiratory Tract Disease 80%
• Synergism 20%
• Tacrolimus 80%

Immunology and Microbiology

• Experimental Transplantation 100%